Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLATE SR vs KALEXATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
10 mg orally once daily.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
55–65% bound to plasma proteins, primarily albumin.
60-70% primarily to albumin
0.4–0.6 L/kg, indicating distribution into total body water.
1.2-1.6 L/kg; indicates extensive extravascular distribution
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
Oral: 85-95%
No dose adjustment required for renal impairment.
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Not approved for pediatric use.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No specific dose adjustment; monitor renal function.
No FDA black box warning exists for this drug.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLATE SR vs KALEXATE, answered by our medical review team.
AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLATE SR and KALEXATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. The standard adult dose of KALEXATE is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLATE SR and KALEXATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.